Deutsche Bank upgraded Humana from Hold to Buy, raising its price target from $235 to $441, signaling confidence in a recovery driven by stabilizing managed care and improving Medicare star ratings. Mizuho also raised its target to $335, citing a more favorable outlook on medical loss ratios. Humana's strong Q1 2026 results and rising Medicare Advantage membership support this positive outlook. However, risks remain, including upcoming star rating results and legal challenges, suggesting cautious optimism for investors.
A Congressional committee found Medicare Advantage overpays insurers by $212 per enrollee, totaling about $7 billion annually. This overpayment funds insurer profits and supplemental benefits like dental and vision care, which traditional Medicare la...
In the first quarter, major US managed care insurers reported earnings that exceeded expectations, leading to stock price increases and raised full-year earnings forecasts. The Centers for Medicare & Medicaid Services announced higher-than-expected 2...
Humana's stock has surged 48% over the past month, outperforming peers like UnitedHealth and Cigna, driven by strong Medicare Advantage (MA) growth and favorable regulatory decisions. The company reported Q1 2026 adjusted EPS of $10.31, beating estim...
Humana Inc. has been upgraded to a Buy rating following a rebound from a more than 65% stock decline. The upgrade is supported by improved CMS rate decisions and activist investor involvement. Despite 2026 earnings per share guidance being below Q1 l...
